During the last session, Axsome Therapeutics Inc. (NASDAQ:AXSM)’s traded shares were 1.27 million, with the beta value of the company hitting 2.47. At the end of the trading day, the stock’s price was $25.34, reflecting an intraday loss of -1.74% or -$0.45. The 52-week high for the AXSM share is $74.10, that puts it down -192.42 from that peak though still a striking 23.52% gain since the share price plummeted to a 52-week low of $19.38. The company’s market capitalization is $1.21B, and the average trade volume was 1.07 million shares over the past three months.
Axsome Therapeutics Inc. (AXSM) received a consensus recommendation of a Buy from analysts. That translates to a mean rating of 1.90. AXSM has a Sell rating from 0 analyst(s) out of 15 analysts who have looked at this stock. 1 analyst(s) recommend to Hold the stock while 0 suggest Overweight, and 13 recommend a Buy rating for it. 1 analyst(s) has rated the stock Underweight. Company’s earnings per share (EPS) for the current quarter are expected to be -$1.03.
Axsome Therapeutics Inc. (NASDAQ:AXSM) trade information
Axsome Therapeutics Inc. (AXSM) registered a -1.74% downside in the last session and has traded in the red over the past 5 sessions. The stock plummet -1.74% in intraday trading to $25.34 this Thursday, 05/12/22, hitting a weekly high. The stock’s 5-day price performance is -31.03%, and it has moved by -33.92% in 30 days. Based on these gigs, the overall price performance for the year is -57.79%.
The consensus price target of analysts on Wall Street is $84.53, which implies an increase of 70.02% to the stock’s current value. The extremes of the forecast give a target low and a target high price of $27.00 and $180.00 respectively. As a result, AXSM is trading at a discount of -610.34% off the target high and -6.55% off the low.
Axsome Therapeutics Inc. (AXSM) estimates and forecasts
Statistics show that Axsome Therapeutics Inc. has underperformed its competitors in share price, compared to the industry in which it operates. Axsome Therapeutics Inc. (AXSM) shares have gone down -33.61% during the last six months, with a year-to-date growth rate less than the industry average at -13.83% against -0.10. Yet analysts are ramping up their growth forecast for the fiscal year 2022. Revenue is predicted to shrink -32.10% this quarter and then drop -30.80% in the quarter after that.
An analysis of the company’s performance over the past 5 years shows that the company’s earnings shrunk an estimated -19.50%. While earnings are projected to return -25.30% in 2022.
Axsome Therapeutics Inc. is due to release its next quarterly earnings between February 28 and March 04. However, it is important to remember that the dividend yield ratio is merely an indicator meant to only serve as guidance.
Axsome Therapeutics Inc. (NASDAQ:AXSM)’s Major holders
Axsome Therapeutics Inc. insiders own 21.42% of total outstanding shares while institutional holders control 52.39%, with the float percentage being 66.67%. Vanguard Group, Inc. (The) is the largest shareholder of the company, while 241 institutions own stock in it. As of Sep 29, 2021, the company held over 2.66 million shares (or 7.05% of all shares), a total value of $87.57 million in shares.
The next largest institutional holding, with 2.07 million shares, is of Blackrock Inc.’s that is approximately 5.49% of outstanding shares. At the market price on Sep 29, 2021, these shares were valued at $68.16 million.
Also, the Mutual Funds coming in first place with the largest holdings of Axsome Therapeutics Inc. (AXSM) shares are Vanguard Total Stock Market Index Fund and Vanguard Small-Cap Index Fund. Data provided on Sep 29, 2021 indicates that Vanguard Total Stock Market Index Fund owns about 0.8 million shares. This amounts to just over 2.13 percent of the company’s overall shares, with a $26.4 million market value. The same data shows that the other fund manager holds slightly less at 0.7 million, or about 1.87% of the stock, which is worth about $23.23 million.